Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study

NCT07699276 is registered in ClinicalTrials.gov with Mahidol University as lead sponsor.

NCT NCT07699276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07699276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study
Lead sponsor
Mahidol University
Phase
Phase 2
Overall status
Recruiting
Start date
February 10, 2026
Completion date
November 15, 2027
Enrollment
95 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer (solid tumors), cisplatin, olanzapine, vomiting